Art. -Nr.: HY-14521

Lometrexol

(Synonyms: DDATHF)

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Lometrexol (DDATHF), an antipurine antifolate, can inhibit the activity of glycinamide ribonucleotide formyltransferase (GARFT) but do not induce detectable levels of DNA strand breaks. Lometrexol can further inhibit de novo purine synthesis, causing abnormal cell proliferation and apoptosis, even cell cycle arrest. Lometrexol has anticancer activity. Lometrexol also is a potent human Serine hydroxymethyltransferase1/2 (hSHMT1/2) inhibitor.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.44%
CAS. Nr.: 106400-81-1
Formel: C₂₁H₂₅N₅O₆
Molecular Weight:443.45

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Lometrexol Chemical Structure

CAS. Nr.: 106400-81-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Antibody-Drug Conjugates

One-stop solution for XDC (ADC/PDC/RDC/ApDC/FDC/ISAC/VDC/SMDC)

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Caspase Isoform-spezifische Produkte anzeigen :

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	>100 μM Compound: Lometrexol	Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line Cytotoxicity in the absence of thymidine and presence of hypoxanthine against CCRF-CEM cell line	[PMID: 10888335]
CCRF-CEM	IC₅₀	>100 μM Compound: Lometrexol	Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line Cytotoxicity in the presence of thymidine and hypoxanthine against CCRF-CEM cell line	[PMID: 10888335]
CCRF-CEM	IC₅₀	0.07 μM Compound: Lometrexol	Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line Cytotoxicity in the absence of hypoxanthine and presence of thymidine against CCRF-CEM cell line	[PMID: 10888335]
CCRF-CEM	IC₅₀	0.13 μM Compound: Lometrexol	Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line Cytotoxicity in the absence of thymidine and hypoxanthine against CCRF-CEM cell line	[PMID: 10888335]
CCRF-CEM	IC₅₀	0.016 μM Compound: DDATHF	Cytotoxicity against human lymphoblastic leukemic CCRF-CEM cell line was evaluated as the concentration required for 50% inhibition of the growth of the control value Cytotoxicity against human lymphoblastic leukemic CCRF-CEM cell line was evaluated as the concentration required for 50% inhibition of the growth of the control value	[PMID: 1552503]
CCRF-CEM	IC₅₀	>100 μM Compound: lometrexol	Antiproliferative activity against human CCRF-CEM cell line in presence of hypoxanthine Antiproliferative activity against human CCRF-CEM cell line in presence of hypoxanthine	[PMID: 16686541]
CCRF-CEM	IC₅₀	0.2 μM Compound: lometrexol	Antiproliferative activity against human CCRF-CEM cell line Antiproliferative activity against human CCRF-CEM cell line	[PMID: 16686541]
CCRF-CEM	IC₅₀	0.2 μM Compound: lometrexol	Antiproliferative activity against human CCRF-CEM cell line in presence of thymidine Antiproliferative activity against human CCRF-CEM cell line in presence of thymidine	[PMID: 16686541]
CCRF-CEM	IC₅₀	25 μM Compound: lometrexol	Antiproliferative activity against FPGS-deficient CCRF-CEM cell line Antiproliferative activity against FPGS-deficient CCRF-CEM cell line	[PMID: 16686541]
CCRF-CEM	IC₅₀	>10 μM Compound: lometrexol, (6R)-5,10-DDATHF	Cytotoxicity against folyl-poly-glutamate synthetase-deficient human CCRF-CEM cells in absence of thymidine and hypoxanthine Cytotoxicity against folyl-poly-glutamate synthetase-deficient human CCRF-CEM cells in absence of thymidine and hypoxanthine	[PMID: 18686942]
CCRF-CEM	IC₅₀	>10 μM Compound: lometrexol, (6R)-5,10-DDATHF	Cytotoxicity against human CCRF-CEM cells in absence of thymidine and presence of hypoxanthine Cytotoxicity against human CCRF-CEM cells in absence of thymidine and presence of hypoxanthine	[PMID: 18686942]
CCRF-CEM	IC₅₀	>100 μM Compound: lometrexol, (6R)-5,10-DDATHF	Cytotoxicity against human CCRF-CEM cells expressing reduced folate carrier in absence of thymidine and hypoxanthine Cytotoxicity against human CCRF-CEM cells expressing reduced folate carrier in absence of thymidine and hypoxanthine	[PMID: 18686942]
CCRF-CEM	IC₅₀	0.2 μM Compound: lometrexol, (6R)-5,10-DDATHF	Cytotoxicity against human CCRF-CEM cells in absence of thymidine and hypoxanthine Cytotoxicity against human CCRF-CEM cells in absence of thymidine and hypoxanthine	[PMID: 18686942]
CCRF-CEM	IC₅₀	0.2 μM Compound: lometrexol, (6R)-5,10-DDATHF	Cytotoxicity against human CCRF-CEM cells in presence of thymidine and absence of hypoxanthine Cytotoxicity against human CCRF-CEM cells in presence of thymidine and absence of hypoxanthine	[PMID: 18686942]
CCRF-CEM	IC₅₀	0.007 μg/mL Compound: 1 (DDATHF)	The compound was tested for its cytotoxicity against CCRF-CEM human leukemic cells using 72 hrs assay The compound was tested for its cytotoxicity against CCRF-CEM human leukemic cells using 72 hrs assay	10.1016/S0960-894X(01)80214-6
CCRF-CEM	IC₅₀	0.007 μg/mL Compound: DDATHF	Tested for the growth inhibition of CCRF-CEM, a human T-cell derived lymphoblastic leukemic cell line Tested for the growth inhibition of CCRF-CEM, a human T-cell derived lymphoblastic leukemic cell line	10.1016/S0960-894X(01)80736-8
CCRF-CEM	IC₅₀	15.2 nM Compound: LTX (2)	Tested in vitro for cellular cytotoxicity against human T-cell derived lymphoblastic leukemia (CCRF-CEM) cells Tested in vitro for cellular cytotoxicity against human T-cell derived lymphoblastic leukemia (CCRF-CEM) cells	10.1016/S0960-894X(97)00041-3
IGROV-1	IC₅₀	16 nM Compound: lometrexol	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells in presence of folic acid	[PMID: 18680275]
IGROV-1	IC₅₀	3.1 nM Compound: lometrexol	Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells Antiproliferative activity against human RFC and FRalpha expressing human IGROV1 cells	[PMID: 18680275]
IGROV-1	IC₅₀	16 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	[PMID: 21879757]
IGROV-1	IC₅₀	3.1 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs Antiproliferative activity against human IGROV1 cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs	[PMID: 21879757]
IGROV-1	IC₅₀	5.77 nM Compound: LMTX	Inhibition of GARFTase in human IGROV1 cells assessed as reduction in [14C]glycine incorporation into [14C]formyl GAR incubated for 15 hrs in complete folate free RPMI medium in presence of 2 nM leucovorin Inhibition of GARFTase in human IGROV1 cells assessed as reduction in [14C]glycine incorporation into [14C]formyl GAR incubated for 15 hrs in complete folate free RPMI medium in presence of 2 nM leucovorin	[PMID: 22243528]
KB	IC₅₀	1.2 nM Compound: lometrexol	Antiproliferative activity against human RFC and FRalpha expressing human KB cells Antiproliferative activity against human RFC and FRalpha expressing human KB cells	[PMID: 18680275]
KB	IC₅₀	14 nM Compound: lometrexol	Inhibition of GARFTase in human KB cells assessed as inhibition of [14C]glycine incorporation into [14C]formylGAR in presence of azaserine Inhibition of GARFTase in human KB cells assessed as inhibition of [14C]glycine incorporation into [14C]formylGAR in presence of azaserine	[PMID: 18680275]
KB	IC₅₀	31 nM Compound: lometrexol	Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid Antiproliferative activity against human RFC and FRalpha expressing human KB cells in presence of folic acid	[PMID: 18680275]
KB	IC₅₀	14 nM Compound: LMX	Inhibition of GARFTase in human KB cells assessed as inhibition of incorporation of [14C]glycine into [14C]formyl GAR after 30 mins in presence of azaserine Inhibition of GARFTase in human KB cells assessed as inhibition of incorporation of [14C]glycine into [14C]formyl GAR after 30 mins in presence of azaserine	[PMID: 19371039]
KB	IC₅₀	14 μM Compound: LMTX, (R)-6-DDATHF	Inhibition of GARFtase in human KB cells assessed as [14C]glycine incorporation in to [14C]FGAR in folate free RPMI medium with 2 nM LCV by in-situassay Inhibition of GARFtase in human KB cells assessed as [14C]glycine incorporation in to [14C]FGAR in folate free RPMI medium with 2 nM LCV by in-situassay	[PMID: 20085328]
KB	IC₅₀	1.2 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs	[PMID: 21879757]
KB	IC₅₀	31 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid Antiproliferative activity against human KB cells expressing human RFC, FRalpha and PCFT assessed as reduction of viable cells after 96 hrs in the presence of 200 nM folic acid	[PMID: 21879757]
KB	IC₅₀	1.2 nM Compound: LMTX, Lometrexol	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay	[PMID: 24111942]
KB	IC₅₀	31 nM Compound: LMTX, Lometrexol	Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid Growth inhibition of human KB cells expressing human RFC/FRalpha/PCFT after 96 hrs by CellTiter-blue assay in presence of folic acid	[PMID: 24111942]
MCF7	IC₅₀	18 μM Compound: 1	Ability to inhibit growth of MCF-7 human breast adenocarcinoma in vitro Ability to inhibit growth of MCF-7 human breast adenocarcinoma in vitro	[PMID: 8027993]
MOLT-4	IC₅₀	1.5 μM Compound: 1	Ability to inhibit [3H]methotrexate transport into MOLT-4 cells in vitro Ability to inhibit [3H]methotrexate transport into MOLT-4 cells in vitro	[PMID: 8027993]
R2	IC₅₀	>1000 nM Compound: lometrexol	Antiproliferative activity against human RFC expressing Chinese hamster R2 cells Antiproliferative activity against human RFC expressing Chinese hamster R2 cells	[PMID: 18680275]
R2	IC₅₀	29.7 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as inhibition of colony formation after 10 to 14 days Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as inhibition of colony formation after 10 to 14 days	[PMID: 21879757]
R2	IC₅₀	38 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs Antiproliferative activity against chinese hamster R2 cells expressing human PCFT assessed as reduction of viable cells after 96 hrs	[PMID: 21879757]
R2	IC₅₀	>1000 nM Compound: LMTX, Lometrexol, 6-(R)DDATHF	Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs Antiproliferative activity against chinese hamster R2 cells assessed as reduction of viable cells after 96 hrs	[PMID: 21879757]
R2	IC₅₀	38 nM Compound: LMTX, Lometrexol	Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay Growth inhibition of Chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTiter-blue assay	[PMID: 24111942]
R2	IC₅₀	38 nM Compound: LMTX, lometrexol	Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay Cytotoxicity against chinese hamster R2 cells expressing human PCFT4 after 96 hrs by CellTitre-Blue fluorescence assay	[PMID: 24256410]
R2	IC₅₀	12 nM Compound: LMTX; (6R)-5,10-dideazatetrahydrofolate	Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis Cytotoxicity in RFC-null Chinese hamster R2 cells assessed as reduction in cell viability measured after 96 hrs by Cell-Titer Blue fluorescence analysis	[PMID: 27458733]

In Vitro

Lometrexol (DDATHF) binds tightly to GART, resulting in a rapid and prolonged depletion of intracellular purine ribonucleotides^[3].
Lometrexol (1-30 μM; 2-10 hours) induces rapid and complete growth inhibition in L1210 cells^[3].
Lometrexol (1 μM; 2-24 hours) induces cell cycle arrest in murine leukemia L1210 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[3]

Cell Line:

Mouse leukemia L1210 cells
Concentration:

1, 30 μM
Incubation Time:

2, 4, 6, 8, 10 hours
Result:

Induced rapid and complete growth inhibition.

Cell Cycle Analysis^[3]

Cell Line:

L1210 cells
Concentration:

1 μM
Incubation Time:

2, 4, 8, 12, 24 hours
Result:

Caused a rapid loss of the G2/M phase population of cells and an early S phase accumulation of cells by 8 hours. By 24 h, the S phase population appeared to be slowly shifting to higher DNA content, and hence, from mid-to-late S phase.

In Vivo

Lometrexol (DDATHF; i.p.; 15-60 mg/kg; on gestation day 7.5) induces neural tube defects (NTDs) by disturbing purine metabolism and increases the rate of embryonic resorption and growth retardation in a dose-dependent manner^[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) decreases glycinamide ribonucleotide formyl transferase (GARFT) activity and Changes of ATP, GTP, dATP and dGTP levels^[1].
Lometrexol (i.p.; 40 mg/kg; on gestation day 7.5) induces abnormal proliferation and apoptosis exist in neural tube defects (NTDs)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (7-8 week, 18-20 g)^[1]
Dosage:

15, 30, 35, 40, 45 and 60 mg/kg
Administration:

Intraperitoneal injection; on gestation day 7.5
Result:

Increased the rate of embryonic resorption and growth retardation in a dose-dependent manner.

Animal Model:

C57BL/6 mice (7-8 week, 18-20 g)^[1]
Dosage:

40 mg/kg
Administration:

Intraperitoneal injection; on gestation day 7.5, for 0, 6, 24, 48 and 96 hours
Result:

Inhibited glycinamide ribonucleotide formyl transferase (GARFT) activity and GARFT activity was maximally inhibited after at 6 hours.
Decreased the levels of ATP, GTP, dATP, and dGTP of NTDs embryonic brain tissue significantly at 6 hours.

Animal Model:

C57BL/6 mice (7-8 week, 18-20 g)^[1]
Dosage:

40 mg/kg
Administration:

Intraperitoneal injection; on gestation day 7.5, for 4 days
Result:

Decreased the expression of proliferation-related genes (Pcna, Foxg1 and Ptch1) and increased the expression of apoptosis-related genes (Bax, Casp8 and Casp9) in NTD groups.

Chemical Information

CAS. Nr. 106400-81-1
Appearance Solid
Molecular Weight 443.45
Formel C₂₁H₂₅N₅O₆
Color White to light yellow
SMILES

O=C1C2=C(NC[C@H](CCC3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)C2)N=C(N)N1
Synonyms

DDATHF
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (5)

All Cell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Nat Commun

Identification of purine biosynthesis as an NADH-sensing pathway to mediate energy stress. [Abstract]

2022 Nov 17;13(1):7031. PMID: 36396642

Lometrexol purchased from MedChemExpress. Usage Cited in: Nat Commun. 2022 Nov 17;13(1):7031. [Abstract]

Effects of purine biosynthesis inhibitors on proliferation of HeLaTet-on EcSTH cells (n = 3 biologically independent samples). Cells were pretreated with the indicated inhibitors for 2 h and counted after treatment with Dox (1 µg/mL) and inhibitors for 48 h. 6-Mercaptopurine (6-MP, 300 µM), pelitrexol (PTrexol, 10 µM), Lometrexol (LTrexol, 10 µM).
Sci Signal

Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]

2024 Nov 26;17(864):eadp1375. PMID: 39591412

Lometrexol purchased from MedChemExpress. Usage Cited in: Sci Signal. 2024 Nov 26;17(864):eadp1375. [Abstract]

Measurements of cell death of 22Rv1 WT and GCN2 KO cells cultured in RPMI or MEM and treated with vehicle or Lometrexol (1 µM) for 6 days.
bioRxiv

2026 May 18.
bioRxiv

2026 May 6.
Res Sq

2025 Jul 18.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (225.50 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2550 mL

11.2752 mL

22.5505 mL

5 mM

0.4510 mL

2.2550 mL

4.5101 mL

10 mM

0.2255 mL

1.1275 mL

2.2550 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (420 KB)
- English - EN (420 KB)
- Français - FR (420 KB)
- Deutsch - DE (420 KB)
- Norwegian - NO (420 KB)
- Español - ES (420 KB)
- Swedish - SV (420 KB)
- Italian - IT (420 KB)
- Korean - KR (420 KB)
- Portuguese - PT (420 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Xu L, et, al. The effect of inhibiting glycinamide ribonucleotide formyl transferase on the development of neural tube in mice. Nutr Metab (Lond). 2016 Aug 23;13(1):56. [Content Brief]

[2]. Scaletti E, et, al. Structural basis of inhibition of the human serine hydroxymethyltransferase SHMT2 by antifolate drugs. FEBS Lett. 2019 Jul;593(14):1863-1873. [Content Brief]

[3]. Bronder JL, et, al. Antifolates targeting purine synthesis allow entry of tumor cells into S phase regardless of p53 function. Cancer Res. 2002 Sep 15;62(18):5236-41. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2550 mL	11.2752 mL	22.5505 mL	56.3761 mL
	5 mM	0.4510 mL	2.2550 mL	4.5101 mL	11.2752 mL
	10 mM	0.2255 mL	1.1275 mL	2.2550 mL	5.6376 mL
	15 mM	0.1503 mL	0.7517 mL	1.5034 mL	3.7584 mL
	20 mM	0.1128 mL	0.5638 mL	1.1275 mL	2.8188 mL
	25 mM	0.0902 mL	0.4510 mL	0.9020 mL	2.2550 mL
	30 mM	0.0752 mL	0.3758 mL	0.7517 mL	1.8792 mL
	40 mM	0.0564 mL	0.2819 mL	0.5638 mL	1.4094 mL
	50 mM	0.0451 mL	0.2255 mL	0.4510 mL	1.1275 mL
	60 mM	0.0376 mL	0.1879 mL	0.3758 mL	0.9396 mL
	80 mM	0.0282 mL	0.1409 mL	0.2819 mL	0.7047 mL
	100 mM	0.0226 mL	0.1128 mL	0.2255 mL	0.5638 mL

Lometrexol

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Lometrexol

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Mitochondria-Targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Lometrexol

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lometrexol

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Mitochondria-Targeted Compound Library

Cell Death Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Mitophagy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Lometrexol

Alle Caspase Isoform-spezifische Produkte anzeigen

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lometrexol Related Classifications

HY-14521 Related Classifications